Abstract
Tailoring a treatment to the special needs of a given individual has always been the overall goal in life and medical sciences. Progress in our understanding the pathophysiology and genetics of complex diseases has strongly contributed to consider many diseases under a new light and to project more sofisticated therapeutic approaches. Providing the right drug at the right dosis to the right patient the right time point is the substantial basis for personalized medicine, away from the classical, more or less evidence based “one size fits for all” model. Although the goal of personalized medicine sound obvious for all stakeholders, the way to reach it remains highly complex and needs the development of many different tools, including biobanks and the identification and validation of biomarkers. We will assist to a progressive change in our definition of the diseases, moving from the phenotypic taxonomy to a molecular taxonomy. The ultimate result will end in a more or less pronounced stratification of complex diseases into variable groups of patients, all characterized by various combinations of phenotypic and endophenotypic profiles. Moreover, this new medical evolutionary process will also induce a shift from the current curative medicine towards a more predictive, preventive, personalized and participatory (P4) medicine.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7(5):201–4.
Roden DM, Tyndale RF. Genomic medicine, precision medicine, personalized medicine: what’s in a name? Clin Pharmacol Ther. 2013;94(2):169–72.
Bieber T. Stratified medicine: a new challenge for academia, industry, regulators and patients. London: Future Science; 2013.
Shen B, Hwang J. The clinical utility of precision medicine: properly assessing the value of emerging diagnostic tests. Clin Pharmacol Ther. 2010;88(6):754–6.
Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, et al. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn. 2003;3(5):573–85.
Eng C. Molecular genetics to genomic medicine practice: at the heart of value-based delivery of healthcare. Mol Genet Genomic Med. 2013;1(1):4–6.
Smart A, Martin P, Parker M. Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics. 2004;18(4):322–42.
Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160(4):636–45.
Bieber T, Cork M, Reitamo S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy. 2012;67(8):969–75.
Suarez-Farinas M, Shah KR, Haider AS, Krueger JG, Lowes MA. Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept. BMC Dermatol. 2010;10:1.
Broder S, Venter JC. Whole genomes: the foundation of new biology and medicine. Curr Opin Biotechnol. 2000;11(6):581–5.
Ocana A, Pandiella A. Personalized therapies in the cancer “omics” era. Mol Cancer. 2010;9:202.
Chen R, Snyder M. Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med. 2013;5(1):73–82.
Bieber T, Broich K. Personalised medicine. Aims and challenges. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(11):1468–72.
Dorfman R, Khayat Z, Sieminowski T, Golden B, Lyons R. Application of personalized medicine to chronic disease: a feasibility assessment. Clin Transl Med. 2013;2(1):16.
van den Broek M, Visser K, Allaart CF, Huizinga TW. Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol. 2013;13(3):463–9.
Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6(4):287–93.
Olson JE, Bielinski SJ, Ryu E, Winkler EM, Takahashi PY, Pathak J, et al. Biobanks and personalized medicine. Clin Genet. 2014;86:50–5.
Suh KS, Sarojini S, Youssif M, Nalley K, Milinovikj N, Elloumi F, et al. Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine. J Oncol. 2013;2013:368751.
Fernald GH, Capriotti E, Daneshjou R, Karczewski KJ, Altman RB. Bioinformatics challenges for personalized medicine. Bioinformatics. 2011;27(13):1741–8.
Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science. 2009;326(5960):1694–7.
Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009;324(5931):1190–2.
Momper JD, Wagner JA. Therapeutic drug monitoring as a component of personalized medicine: applications in pediatric drug development. Clin Pharmacol Ther. 2014;95(2):138–40.
Robison JE, Perreard L, Bernard PS. State of the science: molecular classifications of breast cancer for clinical diagnostics. Clin Biochem. 2004;37(7):572–8.
Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475–82.
Morgan XC, Huttenhower C. Chapter 12: Human microbiome analysis. PLoS Comput Biol. 2012;8(12):e1002808.
Kesselheim AS, Shiu N. The evolving role of biomarker patents in personalized medicine. Clin Pharmacol Ther. 2014;95(2):127–9.
Schleidgen S, Marckmann G. Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system. BMC Med Ethics. 2013;14:20.
Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014;16(3):251–7.
Koelsch C, Przewrocka J, Keeling P. Towards a balanced value business model for personalized medicine: an outlook. Pharmacogenomics. 2013;14(1):89–102.
Hayes DF, Markus HS, Leslie RD, Topol EJ. Personalized medicine: risk prediction, targeted therapies and mobile health technology. BMC Med. 2014;12:37.
Bousquet J, Anto JM, Sterk PJ, Adcock IM, Chung KF, Roca J, et al. Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med. 2011;3(7):43.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bieber, T. (2015). Concept and Scientific Background of Personalized Medicine. In: Bieber, T., Nestle, F. (eds) Personalized Treatment Options in Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45840-2_1
Download citation
DOI: https://doi.org/10.1007/978-3-662-45840-2_1
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-45839-6
Online ISBN: 978-3-662-45840-2
eBook Packages: MedicineMedicine (R0)